Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.13.

Gene editing

Drug Class Company Clinical trial phase
EBT107 Gene-editing CRISPR/Cas 9 Excision Bio, USA Preclinical
ARCUS nucleases Gene-editing ARCUS platform Precision Biosciences, USA Preclinical

IV intravenous